
Lorenzo Falchi, MD
Medical Oncologist
Titles
Assistant Attending Physician
Clinical Expertise
Follicular lymphoma; Diffuse Large B-Cell Lymphoma; Marginal Zone Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia; Peripheral T-Cell Lymphoma; Burkitt Lymphoma; Clinical Trials Research; Immunotherapy; Novel Therapeutic Agents; Personalized Therapy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Falchi accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type:
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): PPO, HMO
Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type:
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type:
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type:
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Contact and Location
- 646-608-3705 Office Phone
- Speaks English and Italian
- New York City
- Memorial Sloan Kettering Nassau Uniondale, NY

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, University of Perugia
Residencies
Internal Medicine - Yale-New Haven Hospital
Fellowships
Medical Oncology - University of Perugia, Italy; Leukemia - MD Anderson Cancer Center; Hematology/Oncology - NewYork-Presbyterian Hospital/Columbia University Medical Center
Board Certifications
Internal Medicine; Hematology; Medical Oncology
As a board-certified medical oncologist and hematologist, I have been passionately dedicated to the study and treatment of blood diseases for well over a decade with a long-standing focus on the care of people with lymphoma. My practice benefits from years of experience that I gained while working at prestigious institutions.
Read more
At MSK, I am fortunate to be part of a multidisciplinary team of experts who share a deep commitment to developing effective therapies for all people with lymphoma. Our staff also provides an exceptional level of care and support for every one of our patients from the first point of contact, so that they are never alone during their time at MSK.
I am also deeply involved in conducting patient-centered research. At MSK, we offer one of the largest clinical trial portfolios for people with all types of lymphoma. I am especially interested in understanding how lymphoma interacts with the immune system. If we know how we can harness the immune system to fight lymphoma, we can develop new immunotherapies that can be used alone or in combination.
A lymphoma diagnosis can be overwhelming and terrifying. Most of my patients are naturally concerned about their future. I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit. I also believe that each person is unique, and my goal is to offer personalized care plans, while using the most effective and innovative treatments available today.
I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit.
-Dr. Falchi
Awards and Honors
- Best Research Fellow for the Leukemia Fellowship Program, MD Anderson Cancer Center (2013)
- Celgene Future Leaders in Hematology Award
- American Society of Hematology Abstract Achievement Award (2018)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Falchi
- A Phase I Study of RO7443904 in Combination with Glofitamab for People with Non-Hodgkin Lymphoma
- A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
- A Phase II Study of Glofitamab Immunotherapy plus R-CHOP for People with Diffuse Large B-Cell Lymphoma
- A Phase II Study of Mosunetuzumab as Initial Chemotherapy-Free Treatment for Follicular Lymphoma
Read more
- Clinical Trials Co-Investigated by Dr. Falchi
- A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
- A Phase I Study of KT-413 in People with B-Cell Non-Hodgkin Lymphoma
- A Phase I Study of Mosunetuzumab Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
- A Phase II Study of ME-401 in People with Recurrent or Persistent Follicular Lymphoma
- A Phase III Study of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin in People with Diffuse Large B-Cell Lymphoma

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
O’Connor OA, Falchi L, Lue J, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual J, Kim HA, Rada A, Atkins L, Khan K, Reilly A, Malanga M, Francescone M, Soderquist C, Park D, Cheng B, Risueno A, Menezes D, Shustov A, Sokol L, Scotto L. Targeting the Peripheral T-cell Lymphoma (PTCL) Epigenome with Oral 5-Azacytidine and Romidepsin Produces Marked Lineage Selective Activity in Patients with Chemotherapy Resistant Disease: A Multicenter Phase 1 Experience. Blood. Published ahead of print.
Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O’Connor OA. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016 Nov 30;9(1):132.
Vitale C,* Falchi L,* (equal contribution), ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory CLL: Correlation Between Responses and Immune Characteristics. Clin Cancer Res. 2016;22(10):2359-67.
Falchi L, Keating MJ, Marom EM, Truong M, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith S, Jain N, Estrov Z, O’Brien S, Lerner S, Ferrajoli A. Correlation between FDG/PET Findings, Histological Features, Clinical Characteristics and Survival in 332 Patients with Chronic Lymphocytic Leukemia. Blood. 2014;123:2783-90.
Visit PubMed for a full listing of Dr. Falchi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lorenzo Falchi discloses the following relationships and financial interests:
-
ADC Therapeutics
Provision of Services -
AbbVie
Provision of Services -
GenMab
Provision of Services
-
Roche
Provision of Services -
Taylor & Francis Group
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].